Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine
VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.